← All trials
NCT05408663
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 11, 2022
- Primary completion
- Jun 13, 2023
- Completion date
- Jul 13, 2023
- First posted
- Jun 7, 2022
- Last posted
- Jul 13, 2022
- Enrollment
- 30
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Extend BiosciencesLead sponsor
- Extend BiosciencesStudy director
- Integrated Medical DevelopmentCollaborator
- National Institutes of Health (NIH)Collaborator
- Pharmaceutical Research Associates, Inc. (PRA)Collaborator
- Extend BiosciencesOfficial
Drugs studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.